Bottom line: “We believe if the recent OMER sell-off is due to the June 25th article, we believe the weakness is unwarranted, overdone, and should be used as a buying opportunity since we do not see any fundamental changes in Omeros’ situation and there are potentially material catalysts remaining in 2015.”
The underwriters were allocated another 697,500 , which is filled, unless retailers have jumped in... which i doubt...
Time to go up now !
Sentiment: Strong Buy
FUNDS exchanging hands
Will NPSP be halted tomorrow or on Friday ? anyone ?
master short seller is actually Adam Feuerestein and Company.
His group appears just before or after or at same time of AF bearish call
Check the latest link on marketpulse
Sentiment: Strong Buy
I wouldn't bet on that Hofno2003 ; you are dead wrong, Takeda too had everything which you claim for Sanofi. Good luck on that.........what applied to Sanofi applied to Takeda too...
so POZN is another SCMP
U.S. drugmaker Sucampo Pharmaceuticals is seeking talks with marketing partner Takeda Pharmaceutical Co Ltd to mend their relationship, after losing a two-year legal battle to sever ties with the Japanese company.
The International Court of Arbitration ruled against Sucampo on Friday in a dispute resulting from the biotechnology company's dissatisfaction with Takeda's marketing of its constipation drug, Amitiza.
The company, which had sought damages and wanted to dissolve its tie-up with Takeda, depends on Amitiza for most of its revenue, derived from royalties paid by Takeda.
Sucampo, which signed the deal with Takeda in 2004, began arbitration in 2010, alleging that its Japanese partner's meek marketing of Amitiza had failed to drive satisfactory sales.
dead money because the partner not really interested in marketing as POZN wanted. Which means lower royalties and in the case POZN partner already has enough enough.... so why would they go for aggressive marketing.. if it sells well and good ... if it doesn't who really cares..
So all the excitement about POZN hitting $20 is premature
you forgot to mention the ultra orphan status for
1) Rindopepimut ( CDX-110 ) is a cancer drug that received orphan drug status in the U.S. and Europe in addition to Fast Track status in the U.S.
2) CDX-1135 DDD is ultra-orphan indication too which means potential for breakthrough status.
Sales and Pricing......hmmmm... between $250K to $300K ?
any approx time frame
CLDX close will be around $24, going up look at RSI, here we go fasten your seat belts